Skip to content

Carrier

Independence Blue Cross

Independence Health Group, Inc. · Drug benefit: Not named in the documents read · 4 documents cited · Read September 2026

Covers weight-loss drugs only where the benefit doesn't exclude them, then requires 5% weight loss to renew Wegovy, Zepbound and Foundayo.

American GLP, Publisher · Who writes this site

Independence Blue Cross puts the benefit question in its policy's first line: weight-loss drugs aren't covered under the pharmacy benefit unless your benefit doesn't exclude them. The criteria only apply to groups that kept the coverage.

For those groups, its weight-loss drug policy asks for a BMI of 30, or 27 with a weight-related condition, and a first approval of 6 months. To stay on Zepbound or Foundayo after 6 months, you need 5% weight loss; for Wegovy the test comes at 7 months.

The policy also covers Wegovy for heart risk and MASH, and Zepbound for sleep apnea, under separate criteria.

Which formulary do these rules cover?

Independence says its posted pharmacy policies apply to the Select and Value formularies. Its Premium formulary is a separate list: it carries Wegovy and the Zepbound auto-injector on tier 2 with prior authorization, marks them as a benefit design option, and excludes the Zepbound KwikPen.

What does the sleep apnea rule require?

For Zepbound and sleep apnea, records must show a BMI of 30 or more and a sleep study with 15 or more breathing events an hour. To renew, you need 5% weight loss in the first 6 months.

Every claim above, with the document behind it

These are the policies we opened and the month we opened them. Each one carries its own policy number and effective date on its face, and those are printed here as the document shows them.

"Weight loss medications are not covered under the pharmacy benefit except for members whose benefit does not exclude weight loss drugs." And: "This Claim Payment Policy is available to those groups that do not exclude weight loss drugs."

Independence Blue Cross, Pharmacy Policy Rx.04.12, Weight Loss Medications for Obesity and Related Health Conditions, effective August 2026 · source

For Zepbound: "Baseline BMI greater than or equal to 30kg/m2 prior to initiating Zepbound therapy" or "Baseline BMI greater than or equal to 27kg/m2 prior to initiating Zepbound therapy" with a weight-related comorbidity, "Initial authorization duration: 6 months", and to continue: "Member has been on therapy for at least 6 months and has had a weight loss of greater than or equal to 5% of baseline body weight".

Independence Blue Cross, Pharmacy Policy Rx.04.12, Weight Loss Medications for Obesity and Related Health Conditions, effective August 2026 · source

For Wegovy and Wegovy HD, reauthorization needs "Member has been receiving Wegovy therapy for up to 7 months and has had a weight loss of greater than or equal to 5% of baseline body weight" and "Member has been adherent to 4 consecutive months of treatment".

Independence Blue Cross, Pharmacy Policy Rx.04.12, Weight Loss Medications for Obesity and Related Health Conditions, effective August 2026 · source

Foundayo: "Baseline BMI greater than or equal to 30kg/m2 prior to initiating orforglipron (Foundayo™) therapy" (or 27 with a comorbidity), with renewal after 6 months on "a weight loss of greater than or equal to 5% of baseline body weight".

Independence Blue Cross, Pharmacy Policy Rx.04.12, Weight Loss Medications for Obesity and Related Health Conditions, effective August 2026 · source

Zepbound for sleep apnea requires records "confirming Body Mass Index (BMI) of greater than or equal to 30kg/m2" and "15 or more obstructive respiratory events per hour of sleep confirmed by a sleep study".

Independence Blue Cross, Pharmacy Policy Rx.04.12, Weight Loss Medications for Obesity and Related Health Conditions, effective August 2026 · source

"For Pharmacy Policies the policies listed on this site only apply to the Select Formulary and Value Formulary."

Independence Blue Cross, Pharmacy policies for providers · source

The 2026 Premium Formulary ("Effective July 1, 2026") lists "WEGOVY 2 PA; ++; QL" and "ZEPBOUND KWIKPEN E", where tier E is excluded and ++ means "Benefit design options – Coverage is determined by your prescription medication benefit plan."

Independence Blue Cross, 2026 Premium Formulary, effective July 2026 · source

Premium formulary quantity limits: "WEGOVY INJ 4 syringes per 28 days" and "ZEPBOUND INJ 4 syringes per 28 days".

Independence Blue Cross, Prior Authorization, Premium Formulary Utilization Management (July 1, 2026), effective July 2026 · source

What these documents cannot tell you

Everything above is what Independence Blue Cross publishes. None of it establishes what your own plan does, and the gap between those two things is wider than a carrier policy makes it look.

  • Whether your group excludes weight-loss drugs isn't public. Your benefit booklet or HR can tell you.
  • Independence says the posted policies apply to its Select and Value formularies. If you're on the Premium formulary, other criteria may apply.
  • A self-funded employer plan administered by Independence can set its own rules.
  • None of this is legal or medical advice. Your plan documents and your notice govern your case.

Where this comes from

  1. Independence Blue Cross, Pharmacy Policy Rx.04.12, Weight Loss Medications for Obesity and Related Health Conditions, effective August 2026 — Open the document
  2. Independence Blue Cross, Pharmacy policies for providers — Open the document
  3. Independence Blue Cross, 2026 Premium Formulary, effective July 2026 — Open the document
  4. Independence Blue Cross, Prior Authorization, Premium Formulary Utilization Management (July 1, 2026), effective July 2026 — Open the document

Where to go next

American GLP is not a law firm, an insurer, a government office or a clinician, and nothing here is legal or medical advice. This page describes what Independence Blue Cross publishes. It is not affiliated with Independence Health Group, Inc., and your own plan documents and your own notice govern your case. Policies carry effective dates and change — read the sources before you act.